• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Announces Received Approval of Insulin Glargine Products in Malaysia
    Gan & Lee Pharmaceuticals Announces Received Approval of Insulin Glargine Products in Malaysia
    Date:2025-02-14

    Beijing, China, Recently– Gan & Lee Pharmaceuticals, a leading global biopharmaceutical company (hereinafter referred to as Gan & Lee, stock code: 603087.SH),announced that its insulin glargine injection and insulin glargine prefilled pen products, developed in collaboration with a major Malaysian pharmaceutical company in Malaysia, have received registration approval from the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. This approval marks the first time Gan & Lee’s insulin products have entered the Malaysian market and serves as a significant milestone in the company’s internationalization strategy, laying a solid foundation for future expansion in the Southeast Asian market.

     

    Malaysia, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), maintains a stringent drug regulatory system. Gan & Lee’s insulin glargine products, bolstered by their impressive clinical trial data from Europe and the United States, have successfully passed NPRA’s rigorous review process. These products, encompassing comprehensive preclinical pharmacological characteristics, PK/PD profiles, and immunogenicity features, align closely with the reference drug Lantus? in terms of quality. This achievement highlights Gan & Lee robust capabilities in quality control and its prowess in international regulatory affairs.

     

    As a key economic hub in Southeast Asia, Malaysia faces a high prevalence rate of diabetes. According to the International Diabetes Federation (IDF) 2021 report, the prevalence of diabetes among individuals aged 20 to 79 in the country stands at 20%, affecting approximately 4.43 million people. The approval of insulin glargine products in Malaysia, compared to second-generation insulin, demonstrates significant clinical advantages, including more stable and long-lasting blood glucose control, as well as a lower incidence of adverse reactions. The introduction of these products will not only improve access to medication and treatment adherence for local diabetes patients but also optimize the overall healthcare resource allocation for diabetes management, better addressing the growing healthcare needs of the local population.

     

    As a leading biopharmaceutical company in China, Gan & Lee has been actively responding to the “Belt and Road” Initiative, aiming to share development opportunities with countries and regions along the “Belt and Road”. To date, the company has established stable partnerships in over 20 countries and regions, including India, Pakistan, and Kazakhstan, providing high-quality treatment solutions for diabetes patients worldwide. The breakthrough in the Malaysian market not only strengthens the deep cooperation between the two companies in production and distribution but also contributes positively to the health and well-being of the Malaysian population. Moving forward, Gan & Lee will continue to uphold the spirit of the “Belt and Road” Initiative, working hand in hand with global partners to provide better, more accessible medicines and services for patients worldwide, contributing to the establishment of a global health community.

     

    References:

    1. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/data/en/country/120/my.html


    About Gan & Lee

    Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

     

    In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網(wǎng)安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 日韩欧美理论片| 日韩在线第二页| 男女作爱免费网站| 少妇无码AV无码一区| 四虎影视成人永久在线观看| 久久久久无码精品亚洲日韩| 香港三日本8A三级少妇三级99| 热久久综合这里只有精品电影| 无码人妻丰满熟妇区免费| 国产亚洲欧美日韩综合综合二区 | 成人午夜视频精品一区| 国产人妖视频一区二区| 久久国产精品99久久小说| 香蕉久久综合精品首页| 日本边添边摸边做边爱边| 国产又粗又猛又黄又爽无遮挡| 久久综合狠狠色综合伊人| 成年人免费的视频| 日本深夜福利19禁在线播放| 国产区女主播在线观看| 中文字幕美日韩在线高清| 给我个免费看片bd| 岳代理孕妇在线风间由美| 免费大片av手机看片| 99热这里有免费国产精品| 波多野结衣中文字幕电影| 国产精品欧美亚洲韩国日本久久 | 国产-第1页-浮力影院| 中国一级特黄毛片| 精品久久久中文字幕人妻| 天天操天天摸天天爽| 亚洲欧美精品伊人久久| 三级网站免费观看| 日韩中文字幕高清在线专区| 国产一区二区视频在线观看| 一级片免费网站| 特级毛片aaaaaa蜜桃| 国产精品夜间视频香蕉| 久久精品人人做人人爽电影蜜月| 香港aa三级久久三级不卡| 成人影院在线观看视频|